Please login to the form below

Not currently logged in
Email:
Password:

autoimmune conditions

This page shows the latest autoimmune conditions news and features for those working in and with pharma, biotech and healthcare.

Medimmune-born Viela files $150m IPO, eyes first product launch

Medimmune-born Viela files $150m IPO, eyes first product launch

been filed for approval with the FDA for a rare autoimmune disease that can lead to blindness and paralysis. ... Viela’s prospectus for the IPO notes it is also planning to start mid-stage studies of inebilizumab in other autoimmune conditions,

Latest news

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Managing medication non-adherence Managing medication non-adherence

    Autoimmune conditions such as Crohn’s disease can flare up through an imbalance of things like stress, lack of sleep or overworking - not just as a direct consequence of nonadherence to ... The latter is a vital service for patients with chronic

  • Taking a lean and careful approach Taking a lean and careful approach

    This fits well with our mission to tackle unmet needs. Autoimmune conditions are increasing and diabetes is at epidemic levels. ... A lot of NASH patients also have these conditions so we want to look at and understand the underlying causes to see what

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    7, 100. Questcor/ Mallinckrodt. Acquisition. Acthar Gel (repository corticotropin) for “difficult-to-treat” autoimmune/ inflammatory conditions.

  • Pharma deals during April 2014 Pharma deals during April 2014

    premium. This gives Mallinckrodt, Acthar Gel (repository corticotropin), which is FDA approved for 19 “difficult-to-treat” autoimmune and inflammatory associated conditions and currently primarily used to treat multiple sclerosis relapses,

  • Deal Watch table for June 2013 Deal Watch table for June 2013

    165. Novartis / Questcor. Development rights. Rights to develop Synacthen (tetracosactide,   melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune &inflammatory conditions).

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Patient Persepective: Autoimmune Disease

    Autoimmune diseases affect 1–5% of the World’s population and have varied symptoms and causes. ... Here we explore with Lois what it is like to live with the symptoms of autoimmune disease, including Crohn’s disease, a form of inflammatory bowel

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanover Communications

Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics